Jiangsu Hengrui Pharmaceuticals Co.,Ltd
1276.HK
Hong Kong Stock Exchange55.15
HKD
+2.60
- -
ISIN
CNE100006XS6
Return %
Stock
S&P500
1Y
-4.58
24.25
3Y
- -
69.87
5Y
- -
74.42
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Feng Ji
- Full Time Employees
- 20,602
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- No. 38, Huanghe Road Lianyungang People's Republic of China 222047
- IPO Date
- May 23, 2025
- Website
- hengrui.com
- Similar Companies
- Business
- Jiangsu Hengrui Pharmaceuticals Co., Ltd. manufactures and markets innovative and high-quality pharmaceutical products, with a broad focus on anticancer therapies, surgical pharmacology, and interventional imaging products, supported by a strong emphasis on R&D and commercialization across global markets. Headquartered in Jiangsu, China, the company operates a vertically integrated model that spans research and development, manufacturing, and global commercial activities, positioning itself as a leading Chinese pharmaceutical enterprise with a significant emphasis on oncology, anesthesia, diagnostic imaging, anti-inflammatory, and cardiovascular medicines. Main products and services - Oncology: innovative anticancer agents across multiple modalities, including small-molecule therapeutics and biologics, with a portfolio targeting prevalent tumor types and advanced disease settings; ongoing development and license collaborations to expand its oncology pipeline. - Anesthetics: a range of anesthetic and perioperative medicines used in surgical settings, incorporating both volatile and injectable formulations to support anesthesia delivery and perioperative care. - Imaging and interventional products: contrast agents and related imaging/instrumentation used in radiology and interventional procedures, designed to enhance diagnostic accuracy and procedural outcomes. - Anti-inflammatory and analgesic therapies: non-steroidal and selective agents addressing inflammatory conditions and pain management, including combination therapies where applicable. - Cardiovascular medicines: therapeutics addressing common cardiovascular diseases, including agents for lipid management, hypertension, heart failure, and other indications. - Prescription pharmaceuticals for hospital and regional markets: a broad portfolio of physician-dispensed and hospital-sold products across multiple therapeutic areas. - Global formulation development and contract manufacturing capabilities: development services and contract manufacturing for pharmaceutical partners to support formulation, scale-up, and clinical supply. Latest major company changes - Strategic licensing and collaborations: enters licensing agreements to expand its oncology reach and accelerate access to innovative cancer therapies through partnerships with global or regional partners. - NRDL and market access developments: announcements regarding inclusion of drugs into national reimbursement lists and expansion of access in major markets, reflecting a strategic shift to broader payer coverage and patient access. - Product pipeline advancement: progress in late-stage trials and regulatory submissions for high-priority oncology assets, alongside expansion of the immuno-oncology and targeted therapy portfolios. - Corporate governance and structural updates: amendments to articles of association or corporate reorganizations aligning with expanded global footprint and strengthening governance for international operations. - Geographic and manufacturing expansion: investments in manufacturing capacity and regional footprints to support rising demand in Asia, Europe, and other regions, including potential new facilities or upgrades to existing sites. Industry context and segments - Industry: pharmaceutical manufacturing and biotechnology - Business segments: R&D and discovery; clinical development; manufacturing and supply chain; marketing, sales, and after-sales support; licensing and partnerships; contract development and manufacturing organization (CDMO) activities. - Target markets: hospitals, specialty clinics, and pharmaceutical distributors in China and international markets; emphasis on oncology, anesthesia, imaging, inflammation, and cardiovascular care. - Geographic operations: China (headquarters and major operations), with ongoing global commercialization in additional regions including Asia-Pacific, Europe, and the Americas through subsidiaries, joint ventures, or licensing agreements. - Corporate structure: independent private sector enterprise with potential parent or affiliate relationships and strategic collaborations to broaden product reach and capabilities. Founding year and headquarters - Founded: 1990s (early corporate history indicates establishment in the 1990s; predominant public-facing materials place development and growth in the late 1990s to early 2000s) - Headquarters: Jiangsu Province, China Subsidiaries and relationships - Maintains a diversified subsidiary network supporting R&D, manufacturing, and international commercialization - Engages in strategic licensing and collaboration arrangements with global pharmaceutical companies to broaden its portfolio and access new markets Note: This description reflects Jiangsu Hengrui Pharmaceuticals Co., Ltd. as a leading Chinese pharmaceutical company with a focus on oncology, anesthesia, imaging, anti-inflammatory, and cardiovascular therapies, while highlighting recent licensing activities, market access developments, and expansion in manufacturing and global partnerships to support its growth trajectory.